Blepharospasm: Clinical Trials

7 trials for Blepharospasm, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed. 7 Phase 2, 2 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 27Completed 7
Phase 32Completed 2
Phase 11Completed 1

Follow Blepharospasm: new trials by email Literature Review of Blepharospasm trials Research Report on Blepharospasm

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm
Dipraglurant, Placebo - Blepharospasm, Dystonia
Phase 2CompletedAddex Pharma S.A.152021-10-062025-10-03
Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm
Cannabidiol Oral Solution [Epidiolex] - Blepharospasm, Blepharospasm, Benign Essential
Phase 2 / Phase 3CompletedSilkiss Eye Surgery122020-05-202021-11-02
Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm
Clostridium Botulinum Toxin Type A - Blepharospasm
Phase 2 / Phase 3CompletedDaewoong Pharmaceutical Co. LTD.2342016-10-012019-06-26
A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm
Acetyl-Hexapeptide Topical Treatment, placebo - Focal Dystonia
Phase 1 / Phase 2CompletedNational Institute of Neurological Disorders and Stroke (NINDS)242009-07-012012-09-06
Brain Stimulation to Treat Blepharospasm or Meige Syndrome
repetitive transcranial magnetic stimulation (rTMS) - Blepharospasm, Focal Dystonia
Phase 2CompletedNational Institute of Neurological Disorders and Stroke (NINDS)222006-06-222017-07-02
Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm
Botulinum toxin type A - Blepharospasm
Phase 2CompletedIpsen1202003-01-012019-07-29
Mexiletine for the Treatment of Focal Dystonia
Mexiletine - Blepharospasm, Dystonia
Phase 2CompletedNational Institute of Neurological Disorders and Stroke (NINDS)241998-07-012008-03-04

Narrower conditions

Dystonia (4)  ·  Dystonic Disorders (3)  ·  Benign essential blepharospasm (1)  ·  Spasm (1)

Broader conditions

Eye Diseases (7)  ·  Eyelid Diseases (7)  ·  Dyskinesias (4)  ·  Nervous System Diseases (4)  ·  Neurologic Manifestations (4)  ·  Pathological Conditions, Signs and Symptoms (4)  ·  Signs and Symptoms (4)  ·  Central Nervous System Diseases (3)  ·  Movement Disorders (3)  ·  Neuromuscular Manifestations (1)

Interventions

Botulinum Toxins, Type A (2)  ·  6-fluoro-2-(4-(pyridin-2-yl)but-3-yn-1-yl)imidazo(1,2-a)pyridine (1)  ·  Cannabidiol (1)  ·  Mexiletine (1)  ·  Transcranial Magnetic Stimulation (1)  ·  abobotulinumtoxinA (1)

Sponsors

National Institute of Neurological Disorders and Stroke (NINDS) (3)  ·  Addex Pharma S.A. (1)  ·  Daewoong Pharmaceutical Co. LTD. (1)  ·  Ipsen (1)  ·  Silkiss Eye Surgery (1)

Countries

United States (6)  ·  South Korea (1)

Results publications

PMID 37606606, PMID 38310362